Abstract Library

#4412 25-years of experience with somatostatin receptor-based therapy in patients with small intestinal neuroendocrine tumours

Introduction: Small intestinal neuroendocrine tumours are well-differentiated and express type 2 somatostatin receptors (SSTR2). Treatment with somatostatin analogues (SSA) (octreotide or lanreotide) has been a cornerstone in controlling tumour growth for 25 years. Peptide Receptor Radionuclide Therapy (PRRT), utilising radiolabelled SSA, was introduced in our institution in May 2009 as primarily 2nd line treatment after progression on SSA. The standard PRRT regimen includes 4 cycles of PRRT (7.4 GBq 177Lu-DOTATATE every eight weeks). Re-treatment protocols remain debated.

Conference:

Presenting Author: Andreassen M

Authors: Slott C, Oturai P, Langer S, Møller S, Hansen C,

Keywords: SSA, PRRT, small intestinal NET,

#4242 Sequential Everolimus and Sunitinib treatment in progressive, advanced, pancreatic NENs: Real-world data from the Belgian Group of Digestive Oncology DNET & NETwerk

Introduction: Everolimus and Sunitinib are often used consecutively for advanced, progressive, well-differentiated pancreatic neuroendocrine tumors (pNET), but to date no data on the optimal sequence is available.

Conference:

Presenting Author: Islam O

Authors: Islam O, van de Vyver G, Verslype C, Borbath I, Decaestecker J,

Keywords: pNEN, Everolimus, Sunitinib, mPFS, mOS, AEs,

#4122 Effectiveness and safety of surufatinib in treating pheochromocytomas and paragangliomas

Introduction: Pheochromocytomas and paragangliomas (PPGLs), classified as malignant by WHO in 2017, are partly catecholamine-secreting neuroendocrine tumors (NET). The 5-year overall survival rate of metastases PPGLs (mPPGL) is only between 50% and 60%. Surufatinib, approved for the treatment of NET, with anti-angiogenic and immunomodulatory properties, offers potential as a potential candidate for treating mPPGL.

Conference:

Presenting Author:

Authors: Su T, Zhong X, Song Q, Wang W,

Keywords: Pheochromocytomas and paragangliomas, treatment, Surufatinib,

#4063 Analysis of the NET G3 of lungs

Introduction: There are still a lot of questions regarding NET G3 subgroup and especially with lungs origin. Neuroendocrine neoplasms account for 20% of lung primary with only 2% for well-differentiated tumors.

Conference:

Presenting Author: Evdokimova E

Authors: Evdokimova E, Markovich A, Delektorskaya V, Yemelyanova G, Kuznetsova A,

Keywords: NET, G3, SSTR, somatostatin analogues, SSA, lung,

#3818 Somatostatin analogues or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors

Introduction: Non-functioning (NF), sporadic, G1-G2 pancreatic neuroendocrine tumors (PanNETs) usually display an indolent course. Surgery is the first-choice treatment for localized tumors >2 cm. Unresectable or metastatic PanNETs expressing somatostatin receptors (SSTRs) are treated with somatostatin analogues (SSAs). The PROMID and the CLARINET studies proved the SSA antiproliferative effect in advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The standard treatment for patients with PanNETs ≤2cm is active surveillance (AS). Yet no evidence of the value of SSA treatment exist in such patient population.

Conference:

Presenting Author: Maratta M

Authors: Maratta M, Chiloiro S, Raia S, Maiorano B, Rossi E,

Keywords: PanNET, somatostatin analogues, efficacy, surveillance, medical treatment,